Allergic Rhinitis in Adults

Overview

Allergic rhinitis (AR) is an IgE-mediated type I hypersensitivity reaction of the nasal mucosa to inhaled environmental allergens, characterized by nasal congestion, rhinorrhea, sneezing, and nasal pruritus. [1] It represents one of the most common chronic conditions globally, affecting 5-15% of the United States population and up to 40% in some countries, with prevalence increasing over recent decades. [2,3] While not life-threatening, AR significantly impacts quality of life (QoL), sleep, work productivity, and school performance, and is strongly associated with comorbid conditions including asthma (38-78% of AR patients), chronic rhinosinusitis, allergic conjunctivitis, and atopic dermatitis. [4,5]

The economic burden is substantial, with direct healthcare costs exceeding $3 billion annually in the US and indirect costs (presenteeism, absenteeism) reaching $32 billion. [5] Notably, AR is often underdiagnosed and undertreated despite availability of effective pharmacotherapy and allergen immunotherapy.

The condition is classified as seasonal (intermittent exposure to pollens) or perennial (year-round exposure to indoor allergens such as house dust mites, animal dander, mold), though many patients have mixed patterns. [6] The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines classify AR by duration (intermittent vs persistent) and severity (mild vs moderate-severe), guiding evidence-based treatment strategies. [7]

---

Epidemiology

Prevalence and Incidence

Epidemiological studies demonstrate a rising global prevalence over the past three decades, attributed to urbanization, increased indoor allergen exposure (dust mites), air pollution, hygiene hypothesis, dietary factors, and climate change extending pollen seasons. [2,10]

Age and Sex Distribution

• Peak onset: Childhood and adolescence (median onset age 8-11 years), though adult-onset AR occurs
• Sex distribution: Slight male predominance in childhood; equal distribution in adults
• Natural history: Symptoms typically improve with age; skin test reactivity wanes after age 50-60 [8]

Risk Factors

---

Aetiology and Pathophysiology

Allergen Types

Seasonal Allergens (Intermittent AR)

Perennial Allergens (Persistent AR)

Immunopathogenesis

Exam Detail: #### Sensitization Phase (First Exposure)

1. Allergen presentation: Inhaled allergens encounter nasal epithelial barrier and dendritic cells
2. T-cell polarization: Dendritic cells present allergen to naive CD4+ T cells, which differentiate into Th2 cells under influence of IL-4
3. IgE production: Th2 cells secrete IL-4 and IL-13, inducing B cells to undergo class switching and produce allergen-specific IgE
4. Mast cell/basophil priming: IgE binds to high-affinity FcεRI receptors on mast cells and basophils
5. Sensitization complete: Individual now sensitized; no symptoms yet

Elicitation Phase (Re-exposure)

Early-Phase Response (Minutes)

1. Allergen cross-linking: Allergen binds to and cross-links surface-bound IgE on mast cells
2. Mast cell degranulation: Immediate release of preformed mediators:
   • Histamine: Binds H1 receptors → vascular permeability, vasodilation, mucus secretion, sensory nerve stimulation
   • Tryptase: Marker of mast cell activation
   • Heparin, chymase: Proteolytic enzymes
3. Newly synthesized mediators (minutes):
   • Leukotrienes (LTC4, LTD4, LTE4): Bronchoconstriction, vascular permeability, mucus hypersecretion
   • Prostaglandin D2: Vasodilation, chemotaxis
   • Platelet-activating factor (PAF): Eosinophil recruitment
4. Clinical manifestations: Sneezing, pruritus, watery rhinorrhea, nasal congestion (mild)

Late-Phase Response (4-8 hours)

1. Cellular infiltration: Recruitment of eosinophils, basophils, Th2 cells, and neutrophils to nasal mucosa
2. Eosinophil activation: Release of:
   • Eosinophil cationic protein (ECP): Epithelial damage
   • Major basic protein (MBP): Cytotoxic to epithelium
   • Eosinophil peroxidase (EPO): Oxidative damage
3. Cytokine release: IL-4, IL-5, IL-13, GM-CSF perpetuate inflammation
4. Nasal hyperreactivity: Non-specific reactivity to irritants (smoke, cold air, strong odors)
5. Clinical manifestations: Persistent nasal congestion, ongoing rhinorrhea, fatigue, impaired cognition

Regulatory Mechanisms

• Type 2 innate lymphoid cells (ILC2s): Produce IL-5 and IL-13, amplifying type 2 inflammation independent of adaptive immunity [6]
• Regulatory T cells (Tregs): Suppressed in AR; allergen immunotherapy increases Tregs, promoting immune tolerance [11]

Epithelial Barrier Dysfunction

Emerging evidence suggests nasal epithelial barrier dysfunction in AR, with decreased tight junction proteins (claudins, occludin) permitting allergen penetration and dendritic cell access. [12] Environmental factors (pollution, cigarette smoke, viral infections) further compromise barrier integrity.

---

Clinical Presentation

Cardinal Symptoms

The classic symptom tetrad of allergic rhinitis (mnemonic: SNIP):

Associated Symptoms

• Ocular symptoms (50-70%): Itching, tearing, redness, chemosis (allergic conjunctivitis)
• Postnasal drip: Throat clearing, cough, hoarseness
• Ear symptoms: Fullness, clicking (Eustachian tube dysfunction)
• Hyposmia/anosmia: Reduced sense of smell (nasal congestion-related)
• Headache/facial pressure: Secondary to sinus ostial obstruction
• Fatigue: Cytokine-mediated; sleep disruption
• Impaired concentration: "Brain fog" from sleep impairment, cytokine effects

Temporal Patterns

Seasonal AR

• Predictable timing: Symptoms coincide with specific pollen seasons
• Rapid onset/offset: Symptoms start within hours-days of allergen exposure
• Geography-dependent: Pollen types vary by region

Perennial AR

• Year-round symptoms: Persistent or fluctuating
• Insidious onset: Gradual development
• Indoor worse: Symptoms exacerbated indoors (dust mites, pets)

Mixed AR

• Baseline perennial symptoms with seasonal exacerbations

Physical Examination Findings

Exam Detail: #### Nasal Examination (Anterior Rhinoscopy/Nasal Endoscopy)

Facial/External Examination

Ocular Examination

• Conjunctival injection: Red, watery eyes
• Chemosis: Conjunctival edema
• Dennie-Morgan lines: Infraorbital skin folds (atopy sign)

Oropharyngeal Examination

• Cobblestoning: Lymphoid hyperplasia on posterior pharynx (postnasal drip)
• Tonsillar hypertrophy: Chronic inflammation

Atypical Presentations

• Isolated nasal congestion: Without other symptoms (consider non-allergic rhinitis)
• Adult-onset AR: New symptoms after age 40 (consider occupational allergens, late-onset asthma)
• Unilateral symptoms: Red flag for structural lesion (polyp, tumor, foreign body)

---

Impact on Quality of Life and Comorbidities

Sleep Disturbance

Nasal congestion impairs nasal airflow, causing:

• Sleep fragmentation: Frequent arousals
• Obstructive sleep apnea (OSA): AR independently associated with 1.8-2.5x increased OSA risk [13]
• Daytime somnolence: Reduced alertness, concentration
• Neurocognitive impairment: Memory, learning, decision-making affected [13]

Work and School Impact

• Presenteeism: Reduced productivity while at work (28-35% reduction in efficiency) [5]
• Absenteeism: 3.6 million lost workdays annually in US
• Academic performance: Lower test scores, reduced learning capacity in students

Psychological Impact

• Reduced QoL scores: SF-36 scores lower than general population
• Mood disturbance: Irritability, depression (10-15% prevalence)
• Social impact: Embarrassment, social withdrawal

Asthma and the Unified Airway

The concept of "one airway, one disease" recognizes AR and asthma as manifestations of unified airway inflammation:

Mechanisms: Common type 2 inflammation, systemic inflammatory spillover, nasal-bronchial reflex, postnasal drip triggering cough/bronchospasm.

Clinical implication: All AR patients should be screened for asthma symptoms (wheeze, dyspnea, chest tightness).

Other Comorbidities

• Chronic rhinosinusitis (CRS): AR predisposes to CRS via ostial obstruction
• Otitis media with effusion: Eustachian tube dysfunction (especially children) [15]
• Allergic conjunctivitis: 40-60% of AR patients
• Atopic dermatitis: Atopic march progression
• Oral allergy syndrome: Cross-reactivity between pollens and food proteins (birch-apple, ragweed-melon)

---

Differential Diagnosis

Rhinitis Classification Framework

Rhinitis is classified as allergic or non-allergic based on IgE-mediated mechanism.

Non-Allergic Rhinitis (NAR) Subtypes

Local Allergic Rhinitis (LAR)

• Definition: IgE-mediated nasal reaction with local (not systemic) IgE production
• Features: Negative serum IgE and skin prick tests, but positive nasal allergen provocation test (NAPT) and nasal IgE [16]
• Prevalence: 25-60% of non-allergic rhinitis cases may be LAR
• Clinical significance: Responds to same treatments as classic AR (intranasal corticosteroids, allergen immunotherapy)

Structural/Anatomic Causes

Red Flags Requiring Further Investigation

Comparative Diagnosis Table

Exam Detail: | Feature | Allergic Rhinitis | Viral URI | Acute Sinusitis | Vasomotor Rhinitis | |---------|-------------------|-----------|-----------------|-------------------| | Onset | Rapid with allergen | Gradual (1-2 days) | Gradual or after URI | Variable | | Duration | Hours-months (seasonal) | 5-10 days | > 10 days | Chronic/episodic | | Nasal discharge | Clear, watery | Clear→mucopurulent | Purulent | Clear, watery | | Sneezing | +++++ | + | + | + | | Pruritus | ++++ | - | - | - | | Fever | - | + | +/- | - | | Facial pain | - | + | +++ | - | | Triggers | Allergen exposure | Contact transmission | URI, obstruction | Temperature, odors | | Seasonality | Present (if seasonal) | Fall/winter | Any | None | | Skin test | Positive | Negative | Negative | Negative |

---

Diagnostic Approach

Clinical Diagnosis

Allergic rhinitis is primarily a clinical diagnosis based on:

1. History: Symptom pattern, triggers, seasonality, family/personal atopy
2. Physical examination: Nasal mucosa appearance, associated findings
3. Response to empiric therapy: Trial of intranasal corticosteroid/antihistamine

Allergy Testing: Indications and Methods

Exam Detail: #### Indications for Testing

• Confirm diagnosis: When clinical diagnosis uncertain
• Identify specific allergens: For avoidance strategies, allergen immunotherapy
• Distinguish AR from NAR: Especially if considering immunotherapy
• Refractory symptoms: Despite empiric treatment

Skin Prick Testing (SPT)

Method:

• Allergen extracts placed on volar forearm or back
• Superficial skin prick (1mm depth)
• Read at 15-20 minutes
• Positive control (histamine), negative control (saline)

Interpretation:

• Positive: Wheal ≥3mm larger than negative control
• Advantages: Rapid (15 minutes), high sensitivity (85-95%), inexpensive
• Disadvantages: Requires stopping antihistamines 3-7 days prior; risk of anaphylaxis (rare); operator-dependent

Contraindications:

• Severe dermatographism
• Extensive eczema
• Antihistamine use (cannot discontinue)
• Severe asthma (relative; risk of systemic reaction)

Serum-Specific IgE Testing

Method:

• Blood sample analyzed for allergen-specific IgE (ImmunoCAP, ELISA)
• Reported as kU/L or classes (0-6)

Interpretation:

• Positive: ≥0.35 kU/L (class 1+) generally considered positive
• Correlation: Higher levels correlate with symptom severity (not absolute)

Advantages:

• No need to stop antihistamines
• Safe (no anaphylaxis risk)
• Useful if SPT unavailable or contraindicated

Disadvantages:

• Lower sensitivity than SPT (75-85%)
• More expensive
• Delayed results (days)
• Possible false positives from cross-reactivity

Component-Resolved Diagnostics (CRD)

• Principle: Test for specific allergenic proteins (e.g., Bet v 1 for birch) rather than whole extracts
• Use: Distinguish genuine sensitization from cross-reactivity; predict immunotherapy response
• Example: Differentiating primary grass pollen allergy from cross-reactivity to birch

Nasal Allergen Provocation Test (NAPT)

• Method: Controlled allergen challenge to nasal mucosa; measure symptom scores and objective parameters (peak nasal inspiratory flow, acoustic rhinometry)
• Indication: Research; diagnosis of local allergic rhinitis (LAR)
• Not routine clinical practice: Specialized centers only

Basophil Activation Test (BAT)

• Research tool: Flow cytometry measuring basophil CD63 expression after allergen stimulation
• Limited clinical use: Expensive, not widely available

Nasal Cytology

• Method: Nasal smear stained for eosinophils
• Eosinophilia (> 20%): Suggests AR or NARES
• Clinical utility: Limited; not routinely performed

Imaging

• Not routinely indicated for AR diagnosis
• CT sinuses: If suspecting chronic rhinosinusitis, nasal polyps, anatomic abnormality, or malignancy
• MRI: Suspected tumor, orbital/intracranial extension

Nasal Endoscopy

• Indication: Refractory symptoms, suspected structural abnormality, chronic rhinosinusitis, nasal polyps
• Findings in AR: Pale, edematous turbinates; clear secretions

---

Classification Systems

ARIA (Allergic Rhinitis and its Impact on Asthma) Classification [7]

The ARIA guidelines replaced the seasonal/perennial classification with a symptom-based system:

By Duration

By Severity

ARIA Treatment Algorithm

Treatment is stepped based on duration + severity:

• Intermittent mild: Oral/intranasal antihistamine OR leukotriene receptor antagonist (LTRA)
• Intermittent moderate-severe: Intranasal corticosteroid (INCS) OR oral antihistamine + INCS
• Persistent mild: INCS OR oral antihistamine OR LTRA
• Persistent moderate-severe: INCS + oral antihistamine; consider allergen immunotherapy

Alternative Classification: Seasonal vs Perennial

Still clinically useful for allergen identification:

---

Management

The ARIA stepwise approach to AR management consists of:

1. Patient education and allergen avoidance
2. Pharmacotherapy tailored to duration and severity
3. Allergen immunotherapy for moderate-severe persistent AR refractory to pharmacotherapy

Allergen Avoidance

Exam Detail: While theoretically ideal, practical effectiveness is limited for many allergens. Evidence quality is generally low-moderate.

Dust Mite Avoidance

Pet Avoidance

• Remove pet from home: Most effective, but often unacceptable to owners
• Exclude pet from bedroom: Moderate benefit; reduces bedroom allergen by 50%
• HEPA air purifiers: Low-moderate benefit; reduces airborne allergen
• Wash pet weekly: Minimal benefit (allergen returns in days)
• Cat-specific: Fel d 1 allergen persists months-years after cat removal

Pollen Avoidance

Mold Avoidance

• Fix leaks/water damage: Prevents mold growth
• Dehumidifiers: Keep humidity less than 50%
• Ventilate bathrooms/kitchens: Exhaust fans
• Avoid leaf piles, compost: Outdoor mold sources

Evidence summary: Allergen avoidance is recommended but insufficient as monotherapy for most patients. Multimodal environmental control combined with pharmacotherapy is most effective. [17]

Pharmacotherapy

Exam Detail: #### Intranasal Corticosteroids (INCS): First-Line Therapy

Mechanism: Potent anti-inflammatory effects via glucocorticoid receptor binding → suppression of inflammatory cytokines (IL-4, IL-5, IL-13), reduced eosinophil/mast cell infiltration, decreased vascular permeability.

Efficacy:

• Most effective single-agent therapy for AR (GRADE: strong recommendation, high-quality evidence) [7,18]
• Reduces all four cardinal symptoms (sneezing, pruritus, rhinorrhea, congestion)
• Especially effective for nasal congestion (superior to antihistamines)
• Improves ocular symptoms in 40-60% (systemic absorption)

Onset: Symptom relief within 12 hours; maximal benefit 1-2 weeks

Commonly Used INCS:

Administration Technique (critical for efficacy):

1. Clear nasal passages (blow nose gently)
2. Shake bottle
3. Aim spray laterally (toward outer eye), away from septum
4. Sniff gently (avoid deep inhalation to pharynx)

Adverse Effects:

• Local: Nasal dryness (10%), epistaxis (minor, 5-10%), nasal irritation, septal perforation (rare, less than 0.1%)
• Systemic: Minimal with modern INCS (bioavailability less than 1%); no HPA axis suppression at recommended doses
• Ocular: Glaucoma/cataracts (not observed in long-term studies with nasal use)

Contraindications:

• Recent nasal surgery/trauma (relative)
• Untreated nasal infection (relative)

Evidence: Cochrane meta-analysis (18 RCTs, n=3,176): INCS significantly superior to placebo for all symptoms; NNT=5 for overall symptom relief. [18]

Oral Antihistamines (H1 Antagonists)

Mechanism: Competitive H1 receptor blockade → prevents histamine-mediated effects (pruritus, sneezing, rhinorrhea, vascular permeability).

Efficacy:

• Effective for: Sneezing, pruritus, rhinorrhea (less effective for congestion)
• Onset: 1-2 hours (rapid relief)
• Ocular symptoms: Reduces itching, tearing

Second-Generation (Non-Sedating) Antihistamines: Preferred

First-Generation (Sedating) Antihistamines: Avoid

Adverse Effects:

• Second-generation: Headache (5-10%), minimal sedation (cetirizine 10%)
• First-generation: Marked sedation (50-70%), impaired driving/cognition, anticholinergic effects, drug interactions (CYP450)

Contraindications:

• Avoid first-generation in: Elderly, pilots/drivers, BPH, glaucoma (anticholinergic effects)

Evidence: GRADE strong recommendation for second-generation antihistamines; effective but inferior to INCS for nasal congestion. [7]

Intranasal Antihistamines

Mechanism: Local H1 blockade + possible anti-inflammatory effects (reduced eosinophils).

Efficacy:

• Effective for all symptoms; comparable to oral antihistamines
• Faster onset than INCS (minutes vs hours)
• Combination INCS + intranasal antihistamine superior to either alone [19]

Adverse Effects: Bitter taste, epistaxis (5-10%)

Intranasal Decongestants (α-Adrenergic Agonists)

Mechanism: Vasoconstriction → rapid decongestion

Efficacy: Rapid, potent relief of congestion (within minutes)

Critical Limitation: Rhinitis medicamentosa (rebound congestion) develops after 5-7 days continuous use → worsening congestion, dependence

Indication: Short-term use only (≤3-5 days) for severe congestion during acute exacerbation

Oral Decongestants

Mechanism: Systemic α-adrenergic agonism → vasoconstriction

Efficacy: Modest reduction in congestion (pseudoephedrine); phenylephrine oral formulation now considered ineffective [20]

Adverse Effects:

• CNS stimulation: Insomnia, nervousness, irritability
• Cardiovascular: Tachycardia, hypertension, arrhythmia
• Urinary retention (especially elderly males with BPH)

Contraindications:

• Severe/uncontrolled hypertension
• Coronary artery disease
• Hyperthyroidism
• Monoamine oxidase inhibitor (MAOI) use
• Glaucoma (narrow-angle)

Evidence: Pseudoephedrine modestly effective; avoid in cardiovascular disease. Oral phenylephrine ineffective and should not be used. [20]

Leukotriene Receptor Antagonists (LTRAs)

Mechanism: Blocks cysteinyl leukotriene receptors (CysLT1) → reduces inflammation, mucus, vascular permeability

Efficacy:

• Less effective than INCS or antihistamines as monotherapy
• Modest improvement in all symptoms
• Benefit in AR + asthma comorbidity: Treats both conditions

Adverse Effects: Headache, GI upset; neuropsychiatric effects (mood changes, depression, suicidal ideation) in some patients (FDA black box warning)

Role: Second-line agent; consider if concurrent asthma or patient refuses INCS/antihistamines

Intranasal Anticholinergics

Mechanism: Muscarinic receptor blockade → reduces cholinergic-mediated mucus secretion

Efficacy: Effective for rhinorrhea only (not congestion, sneezing, pruritus)

Indication: Rhinorrhea-predominant AR or non-allergic rhinitis (especially gustatory rhinitis)

Adverse Effects: Nasal dryness, epistaxis, anticholinergic (minimal systemic absorption)

Intranasal Cromones (Mast Cell Stabilizers)

Mechanism: Mast cell stabilization → prevents degranulation

Efficacy: Modest; inferior to INCS and antihistamines

Indication: Mild AR; prophylactic use before allergen exposure

Adverse Effects: Minimal; local irritation

Limitation: Requires QID dosing; must start before allergen exposure

Combination Products

Efficacy: Faster onset and greater symptom relief than INCS monotherapy

Pharmacotherapy Summary: ARIA Guideline Recommendations [7]

Exam Detail: | AR Severity | First-Line | Second-Line | Additional Options | |-------------|------------|-------------|-------------------| | Intermittent mild | Oral H1-antihistamine OR INCS | Switch or combine | LTRA | | Intermittent moderate-severe | INCS OR oral H1-antihistamine + INCS | Intranasal antihistamine | Add oral decongestant (short-term) | | Persistent mild | INCS OR oral H1-antihistamine | Combine INCS + antihistamine | LTRA | | Persistent moderate-severe | INCS + oral H1-antihistamine | Add intranasal antihistamine or LTRA | Consider allergen immunotherapy |

Step-Up/Step-Down Approach:

• Step up: If inadequate control after 2-4 weeks
• Step down: After sustained control (e.g., after pollen season)

Allergen Immunotherapy (AIT)

Exam Detail: Allergen immunotherapy is the only disease-modifying treatment for AR, inducing immune tolerance and providing long-term benefit even after discontinuation. [11,21]

Indications

• Moderate-severe persistent AR inadequately controlled by pharmacotherapy
• Patient preference to reduce long-term medication use
• Comorbid allergic asthma (AIT reduces asthma symptoms and bronchial hyperreactivity)
• Specific allergen identified by skin testing or specific IgE

Contraindications

• Absolute: Severe uncontrolled asthma (FEV1 less than 70% predicted), active malignancy, immune deficiency
• Relative: Pregnancy (do not initiate; may continue if tolerated), beta-blocker use (risk of anaphylaxis refractory to epinephrine), cardiovascular disease (SCIT)

Subcutaneous Immunotherapy (SCIT)

Method:

• Injections of increasing allergen doses (build-up phase: 3-6 months)
• Maintenance phase: Monthly injections for 3-5 years

Efficacy:

• Symptom reduction: 25-40% reduction in symptom scores [21]
• Medication reduction: 30-50% reduction in need for pharmacotherapy
• Long-term benefit: Sustained efficacy 7-12 years post-discontinuation
• Prevents asthma: Reduces risk of asthma development in AR patients (NNT=5) [14]

Adverse Effects:

• Local: Injection site swelling/pruritus (common, 50%)
• Systemic: Urticaria, rhinitis, asthma exacerbation (10-15%)
• Anaphylaxis: 0.1-0.2% of injections; fatalities rare (1 per 2.5 million injections)

Administration:

• Must be administered in supervised medical setting with epinephrine available
• Observe 30 minutes post-injection

Evidence: Cochrane meta-analysis (51 RCTs): SCIT significantly improves symptom scores (SMD -0.73) and reduces medication use. [21]

Sublingual Immunotherapy (SLIT)

Method:

• Daily sublingual tablets or drops (allergen extract)
• No build-up phase (fixed dose)
• Duration: 3 years minimum

Formulations:

• Grass pollen tablets: Oralair, Grazax
• Ragweed tablets: Ragwitek
• Dust mite tablets: Odactra

Efficacy:

• Symptom reduction: 15-30% reduction (slightly less than SCIT)
• Medication reduction: 20-40% reduction
• Long-term benefit: Sustained 2-3 years post-treatment

Adverse Effects:

• Local (common): Oral pruritus (60-70%), mouth/throat swelling (10%), GI upset (5%)
• Systemic reactions: Rare (less than 5%)
• Anaphylaxis: Extremely rare; can be self-administered at home after first dose in clinic

Administration:

• First dose supervised (clinic)
• Subsequent doses at home (daily)

Advantages over SCIT:

• Home administration (convenience)
• No injections
• Lower anaphylaxis risk
• Preferred by patients

Disadvantages:

• Lower efficacy than SCIT
• Daily adherence required (dropout rate 20-30%)
• Expensive

Evidence: Cochrane meta-analysis (42 RCTs): SLIT significantly improves symptom scores (SMD -0.49) and reduces medication use; safer than SCIT. [22]

Mechanism of AIT

1. Shift from Th2 to Th1/Treg response: Increased Tregs secreting IL-10, TGF-β → immune tolerance
2. IgG4 production: Blocking antibodies compete with IgE for allergen binding
3. Reduced mast cell/basophil reactivity: Decreased degranulation
4. Decreased eosinophil infiltration: Reduced tissue inflammation

Patient Selection for AIT

Ideal candidate:

• Moderate-severe persistent AR
• Limited allergen sensitization (1-3 allergens)
• Specific allergen identified
• Inadequate pharmacotherapy response
• Motivated for long-term treatment

Poor candidate:

• Mild intermittent AR well-controlled with medications
• Multiple allergen sensitivities (> 5 allergens)
• Severe uncontrolled asthma
• Poor compliance

Surgical Interventions

Exam Detail: Surgery is not a primary treatment for AR but addresses structural comorbidities or refractory symptoms.

Indications

• Nasal polyposis refractory to medical management (CRSwNP)
• Severe septal deviation or turbinate hypertrophy causing obstruction
• Chronic rhinosinusitis refractory to medical treatment

Procedures

Evidence: Limited benefit for AR symptoms alone; combined medical + surgical management optimal for CRSwNP.

Emerging Therapies

Exam Detail: #### Biologics

• Omalizumab (anti-IgE mAb):

  • "Indication: Severe AR refractory to conventional treatment (off-label; approved for asthma, chronic urticaria)"
  • "Mechanism: Binds free IgE, preventing mast cell binding"
  • "Efficacy: Reduces AR symptom scores 30-50%"
  • "Limitation: Expensive; subcutaneous injection q2-4 weeks"

• Dupilumab (anti-IL-4Rα mAb):

  • "Indication: CRSwNP (approved); AR under investigation"
  • "Mechanism: Blocks IL-4/IL-13 signaling → reduced type 2 inflammation"
  • "Efficacy: Promising in trials; reduces nasal polyps, improves symptoms"

Intranasal Phototherapy

• Mechanism: Narrow-band UV light reduces mast cells, eosinophils
• Evidence: Limited; not widely adopted

---

Special Populations

Pregnancy and Lactation

Exam Detail: AR prevalence and severity may increase during pregnancy (hormonal effects on nasal vasculature).

Pharmacotherapy in Pregnancy

AIT during pregnancy:

• Do not initiate SCIT or SLIT
• Continue maintenance if tolerated and no systemic reactions

Lactation: INCS, antihistamines (cetirizine, loratadine) considered safe; minimal systemic absorption/excretion in breast milk.

Paediatric Considerations

• Diagnosis: Same criteria; rule out adenoidal hypertrophy, foreign body
• Pharmacotherapy: INCS and antihistamines safe in children; dose-adjusted
• Growth: Modern INCS do not affect growth at recommended doses (long-term studies reassuring)
• AIT: SLIT approved for children ≥5 years (dust mite, grass, ragweed)

Elderly

• Comorbidities: Consider drug interactions, cardiovascular disease (avoid decongestants)
• Anticholinergic burden: Avoid first-generation antihistamines (sedation, falls, delirium risk)
• INCS: Safe; preferred first-line therapy

Occupational Rhinitis

• Definition: AR symptoms triggered by workplace allergens (latex, flour, animals, wood dust, chemicals)
• Diagnosis: Symptom diary (work-related pattern), skin testing to occupational allergens, workplace challenge
• Management: Allergen avoidance (engineering controls, PPE), pharmacotherapy, consider job modification/relocation
• Legal: May qualify for workers' compensation

---

Prognosis and Natural History

Untreated Course

• Childhood onset: Symptoms peak in adolescence, often improve in adulthood (30-50% experience spontaneous remission)
• Adult onset: More likely to persist
• Complications: Progression to asthma (20-40%), chronic rhinosinusitis, sleep disturbance, impaired QoL

Treated Course

• Pharmacotherapy: Effective symptom control; requires ongoing use
• Allergen immunotherapy: Disease-modifying; sustained benefit 7-12 years post-treatment; prevents asthma development [14,21]

Prognostic Factors

---

Prevention and Screening

Primary Prevention

Evidence for preventing AR sensitization is limited and conflicting:

• Breastfeeding: May reduce atopy risk in high-risk infants (inconsistent evidence)
• Allergen avoidance (infancy): No clear benefit; "hygiene hypothesis" suggests early diverse allergen exposure may be protective
• Probiotics: Insufficient evidence for AR prevention
• Vitamin D: Under investigation; inconsistent results

Current consensus: No established primary prevention strategy for AR.

Secondary Prevention (Screening)

• No population screening programs for AR
• Clinical screening: Assess AR symptoms in patients with asthma, atopic dermatitis, chronic rhinosinusitis (high comorbidity)
• Asthma screening: All AR patients should be asked about asthma symptoms (cough, wheeze, dyspnea, chest tightness)

Tertiary Prevention (Preventing Complications)

• Allergen immunotherapy: Prevents asthma development in AR patients [14]
• Optimal AR control: Reduces asthma exacerbations, improves asthma control
• Sleep screening: Assess for sleep-disordered breathing, OSA [13]

---

Key Guidelines

ARIA (Allergic Rhinitis and its Impact on Asthma) Guidelines 2020 [7]

Organization: International expert consensus (Bousquet et al.)

Key Recommendations:

1. Classify AR by duration (intermittent/persistent) and severity (mild/moderate-severe)
2. INCS first-line for persistent moderate-severe AR (GRADE: strong)
3. Oral antihistamines effective for mild AR or intermittent symptoms
4. Allergen immunotherapy for refractory moderate-severe AR
5. Mobile health technology for monitoring and real-world evidence

Japanese Guidelines for Allergic Rhinitis 2020 [6]

Organization: Japanese Society of Allergology

Unique Features:

• Emphasis on sublingual immunotherapy (dual therapy for dust mite + Japanese cedar pollen)
• Surgical classification for turbinate reduction, posterior nasal neurectomy
• Anti-IgE mAb (omalizumab) for severe AR

AAO-HNSF Clinical Practice Guideline: Allergic Rhinitis 2015

Organization: American Academy of Otolaryngology–Head and Neck Surgery Foundation

Key Recommendations:

1. Clinicians should distinguish AR from non-allergic rhinitis
2. INCS first-line for moderate-severe AR
3. Assess impact on QoL
4. Offer allergen immunotherapy for inadequate pharmacotherapy response

---

Common Exam Questions

Written Exam (MCQ/SBA)

1. "A 28-year-old woman presents with bilateral nasal congestion, watery rhinorrhea, sneezing, and itchy eyes every spring for the past 5 years. Which medication is most effective for her nasal congestion?"

   • Answer: Intranasal corticosteroid (most effective for congestion) [7,18]

2. "A patient with perennial allergic rhinitis has inadequate symptom control despite fluticasone nasal spray and cetirizine. Skin prick testing is positive for dust mite. What is the next most appropriate step?"

   • Answer: Refer for allergen immunotherapy (SCIT or SLIT) [7,21]

3. "Which AR symptom is least responsive to oral antihistamines?"

   • Answer: Nasal congestion (histamine is not the primary mediator of congestion; antihistamines most effective for sneezing, pruritus, rhinorrhea)

4. "A patient using oxymetazoline nasal spray for 2 weeks develops worsening nasal congestion. What is the diagnosis?"

   • Answer: Rhinitis medicamentosa (rebound congestion from prolonged topical decongestant use)

5. "Which investigation confirms the diagnosis of allergic rhinitis?"

   • Answer: Skin prick testing or serum-specific IgE (demonstrates IgE-mediated sensitization)

Viva Voce (Oral Exam)

Viva Point: Opening statement: "Allergic rhinitis is an IgE-mediated type I hypersensitivity reaction of the nasal mucosa to inhaled allergens, characterized by nasal congestion, rhinorrhea, sneezing, and pruritus. It affects 10-40% of the global population and is strongly associated with asthma, with up to 78% of asthmatics having comorbid AR."

Examiner: "How do you classify allergic rhinitis?"

"The ARIA guidelines classify AR by duration—intermittent (symptoms less than 4 days/week or less than 4 weeks) versus persistent (≥4 days/week and ≥4 weeks)—and by severity—mild (normal sleep, activities, work/school) versus moderate-severe (impairment in any of these domains). Traditionally, AR was also classified as seasonal (pollens) or perennial (dust mites, pets, mold), which remains useful for allergen identification."

Examiner: "Describe the immunopathogenesis."

"AR is a type I hypersensitivity reaction. During sensitization, allergen-presenting dendritic cells activate naive CD4+ T cells, which differentiate into Th2 cells secreting IL-4 and IL-13. These cytokines drive B-cell class switching to produce allergen-specific IgE, which binds to FcεRI receptors on mast cells and basophils. Upon re-exposure, allergen cross-links IgE, triggering mast cell degranulation and release of histamine, leukotrienes, and prostaglandins. This produces the early-phase response—sneezing, pruritus, rhinorrhea—within minutes. The late-phase response occurs 4-8 hours later, characterized by eosinophil and Th2 cell infiltration, cytokine release (IL-5, IL-13), and persistent nasal congestion."

Examiner: "What is the first-line pharmacotherapy for moderate-severe persistent AR?"

"Intranasal corticosteroids are first-line, as they are the most effective single-agent therapy, addressing all four cardinal symptoms and particularly effective for nasal congestion. Fluticasone and mometasone are commonly used, with maximal benefit in 1-2 weeks. They have minimal systemic absorption and excellent safety profiles. For inadequate control, I would add an oral second-generation antihistamine such as cetirizine or loratadine."

Examiner: "When would you refer for allergen immunotherapy?"

"I would consider allergen immunotherapy for patients with moderate-severe persistent AR who have inadequate symptom control despite optimal pharmacotherapy, or who prefer to reduce long-term medication use. The patient must have specific allergen sensitization confirmed by skin prick testing or serum-specific IgE, ideally to a limited number of allergens (1-3). AIT is the only disease-modifying treatment, inducing immune tolerance and providing sustained benefit years after discontinuation. It also reduces the risk of asthma development in AR patients. Contraindications include severe uncontrolled asthma and active malignancy."

Examiner: "How does AR relate to asthma?"

"AR and asthma represent unified airway disease. Up to 78% of asthmatics have AR, and 20-40% of AR patients have asthma. AR is a significant risk factor for asthma development, increasing the risk 3-5-fold. Poorly controlled AR worsens asthma outcomes, and treating AR improves asthma control. The mechanisms include shared type 2 inflammation, systemic inflammatory spillover, nasal-bronchial reflexes, and postnasal drip. Therefore, all AR patients should be screened for asthma symptoms."

Common Mistakes in Exams

Mistakes that fail candidates:

❌ Missing the unified airway concept: Failing to screen AR patients for asthma or mention the bidirectional relationship

❌ Prescribing oral phenylephrine: Recent FDA evidence shows oral phenylephrine is ineffective (bioavailability less than 1%) [20]

❌ Recommending prolonged topical decongestants: Not warning about rhinitis medicamentosa after 5-7 days of use

❌ Stating antihistamines are first-line for moderate-severe persistent AR: INCS are superior (GRADE guidelines)

❌ Confusing AR with non-allergic rhinitis: Not recognizing that negative skin tests/IgE exclude classic AR (consider local AR or NAR)

❌ Not considering allergen immunotherapy: Missing the only disease-modifying treatment for refractory AR

❌ Using first-generation antihistamines in elderly: High anticholinergic burden (sedation, falls, delirium, urinary retention)

❌ Initiating allergen immunotherapy in pregnancy: Contraindicated to start (can continue maintenance if tolerated)

Model Answers

Q: "Describe your approach to a patient presenting with perennial nasal congestion, rhinorrhea, and sneezing."

A: "I would approach this systematically. First, I would take a detailed history focusing on symptom characteristics, timing (seasonal vs perennial), triggers (allergens, irritants), impact on sleep and daily activities, personal and family history of atopy, and comorbidities such as asthma. On examination, I would perform anterior rhinoscopy or nasal endoscopy looking for pale, boggy turbinates and clear rhinorrhea (suggestive of AR) versus purulent discharge (sinusitis) or unilateral findings (structural lesion). I would also examine for allergic shiners, conjunctival injection, and pharyngeal cobblestoning. If the history and exam suggest allergic rhinitis, I would confirm with skin prick testing or serum-specific IgE to common allergens (dust mite, pet dander, molds) and screen for asthma. For moderate-severe persistent AR based on ARIA criteria, I would initiate intranasal corticosteroid (fluticasone or mometasone) as first-line therapy, provide allergen avoidance counseling, and review in 2-4 weeks. If inadequate control, I would add an oral second-generation antihistamine and consider referral for allergen immunotherapy."

---

Clinical Pearls

Diagnostic Pearls

• Pruritus is the hallmark of allergy: Nasal, palatal, or ocular itching strongly suggests AR over infectious or vasomotor rhinitis
• Clear, watery rhinorrhea: Allergic; purulent suggests infection
• Bilateral symptoms: AR; unilateral warrants imaging (foreign body, tumor, polyp)
• Pale, boggy turbinates: AR; erythematous turbinates suggest infection or vasomotor rhinitis
• "Allergic salute" and "allergic shiners": Classic pediatric signs from chronic pruritus and venous congestion
• Cobblestoning of posterior pharynx: Indicates chronic postnasal drip
• Seasonal pattern: Tree pollen (spring), grass (late spring/summer), ragweed (fall)
• Worse indoors: Suggests perennial allergens (dust mites, pets)
• Worse at night: Dust mite exposure (bedding) or supine position (congestion)

Treatment Pearls

• INCS are most effective for nasal congestion: Superior to antihistamines
• Correct INCS technique is critical: Aim laterally (toward outer eye), not at septum; prevents epistaxis and septal perforation
• Start INCS 1-2 weeks before pollen season: Preventive use more effective than reactive
• Combination INCS + intranasal antihistamine (e.g., Dymista) superior to either alone [19]
• Second-generation antihistamines preferred: Less sedation, fewer anticholinergic effects than first-generation
• Avoid topical decongestants > 5 days: Rhinitis medicamentosa (rebound congestion)
• Oral phenylephrine is ineffective: FDA evidence shows less than 1% bioavailability [20]
• Montelukast useful in AR + asthma: Treats both conditions but less effective than INCS for AR alone
• Allergen immunotherapy is disease-modifying: Only treatment providing sustained benefit post-discontinuation; prevents asthma development
• SLIT safer than SCIT: Lower anaphylaxis risk, home administration; but slightly less efficacious

Disposition and Follow-Up Pearls

• Screen all AR patients for asthma: Ask about cough, wheeze, dyspnea, chest tightness (unified airway)
• Assess quality of life and sleep: Untreated AR significantly impairs both
• Allergen avoidance counseling: Dust mite encasings, pet removal, pollen avoidance (limited efficacy as monotherapy but adjunctive)
• Review inhaler technique for INCS: Poor technique reduces efficacy
• Long-term INCS use is safe: Modern formulations have minimal systemic effects; no HPA suppression, growth impairment, or osteoporosis at therapeutic doses
• Refer to allergist for: Diagnostic uncertainty, inadequate response to pharmacotherapy, allergen immunotherapy candidacy, occupational rhinitis

Red Flags Requiring Urgent Investigation

• Unilateral nasal symptoms: Suspect tumor, foreign body, or polyp → imaging, endoscopy
• Blood-tinged discharge: Neoplasm, granulomatous disease → ENT referral
• Severe anosmia: CRSwNP, tumor, neurodegenerative disease
• Cranial neuropathy, proptosis: Malignancy with orbital/intracranial invasion → urgent imaging, ENT referral
• Constitutional symptoms (fever, weight loss): Granulomatous disease (GPA, sarcoidosis), malignancy

---

References

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1 Suppl):S2-8. doi:10.1067/mai.2001.115569

2. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc. 2000;21(1):1-6. doi:10.2500/108854100778248971

3. Bellanti JA, Wallerstedt DB. Allergic rhinitis update: Epidemiology and natural history. Allergy Asthma Proc. 2000;21(6):367-70. doi:10.2500/108854100778249088

4. Casale TB, Dykewicz MS. Clinical implications of the allergic rhinitis-asthma link. Am J Med Sci. 2004;327(3):127-138. doi:10.1097/00000441-200403000-00004

5. Patel KB, Mims JW, Clinger JD. The burden of asthma and allergic rhinitis: epidemiology and health care costs. Otolaryngol Clin North Am. 2024;57(2):179-189. doi:10.1016/j.otc.2023.09.007

6. Okano M, Kurono Y, Ichimura K, et al. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020;69(3):331-345. doi:10.1016/j.alit.2020.04.001

7. Bousquet J, Schunemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. doi:10.1016/j.jaci.2019.06.049

8. Parikh A, Scadding GK. Seasonal allergic rhinitis. BMJ. 1997;314(7091):1392-5. doi:10.1136/bmj.314.7091.1392

9. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809):2112-2122. doi:10.1016/S0140-6736(11)60130-X

10. Izquierdo-Dominguez A, Valero AL, Mullol J. Comparative analysis of allergic rhinitis in children and adults. Curr Allergy Asthma Rep. 2013;13(2):142-51. doi:10.1007/s11882-012-0331-y

11. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-725.e5. doi:10.1016/j.jaci.2011.12.973

12. Steelant B, Farré R, Wawrzyniak P, et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol. 2016;137(4):1043-1053.e5. doi:10.1016/j.jaci.2015.10.050

13. Pagel JML, Mattos JL. Allergic rhinitis and its effect on sleep. Otolaryngol Clin North Am. 2024;57(2):319-328. doi:10.1016/j.otc.2023.09.003

14. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948. doi:10.1111/j.1398-9995.2007.01451.x

15. Vlastos IM, Tsotsiou N, Almomani M, et al. Is allergic rhinitis related to otitis media with effusion in adults and children? Applying epidemiological guidelines for causation. Cells. 2025;14(11):805. doi:10.3390/cells14110805

16. Campo P, Eguiluz-Gracia I, Bogas G, et al. Local allergic rhinitis: implications for management. Clin Exp Allergy. 2019;49(1):6-16. doi:10.1111/cea.13192

17. Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2010;(7):CD001563. doi:10.1002/14651858.CD001563.pub3

18. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5):479-484. doi:10.1016/S1081-1206(10)62084-8

19. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10. doi:10.1016/j.jaci.2012.01.077

20. Hatton RC, Winterstein AG, McKelvey RP, et al. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother. 2007;41(3):381-390. doi:10.1345/aph.1H679

21. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;(1):CD001936. doi:10.1002/14651858.CD001936.pub2

22. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740-752. doi:10.1111/j.1398-9995.2011.02583.x